Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Recruitment status is updated to indicate that no participants are being sought. The page also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and standardizes the Intervention/Treatment heading, along with a revision update from v3.5.5 to v3.6.0.
    Difference
    0.5%
    Check dated 2026-06-15T19:09:04.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.5.4 to v3.5.5, signaling a small update to the page’s underlying version. This change reflects an internal patch or improvement rather than a modification to the study content.
    Difference
    0.1%
    Check dated 2026-06-08T15:19:35.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    A new page revision tag v3.5.4 is added, replacing v3.5.3, indicating an updated version of the study page.
    Difference
    0.1%
    Check dated 2026-05-18T03:53:00.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page’s displayed release/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a site/system update rather than a change to the study record content.
    Difference
    0.1%
    Check dated 2026-04-26T15:19:52.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Revision number updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-19T13:36:41.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    Removed Hepatocellular carcinoma from the Conditions list and removed the Genetic and Rare Diseases Information Center resource under Resources.
    Difference
    0.2%
    Check dated 2026-03-28T23:40:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.